JUBLPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.6
| Stock Code | JUBLPHARMA | Market Cap | 15,747 Cr. | Current Price | 989 ₹ | High / Low | 1,250 ₹ |
| Stock P/E | 502 | Book Value | 145 ₹ | Dividend Yield | 0.50 % | ROCE | 1.80 % |
| ROE | 1.35 % | Face Value | 1.00 ₹ | DMA 50 | 950 ₹ | DMA 200 | 982 ₹ |
| Chg in FII Hold | -0.06 % | Chg in DII Hold | 0.40 % | PAT Qtr | 65.7 Cr. | PAT Prev Qtr | 6.60 Cr. |
| RSI | 58.1 | MACD | 22.3 | Volume | 64,118 | Avg Vol 1Wk | 2,43,535 |
| Low price | 784 ₹ | High price | 1,250 ₹ | PEG Ratio | -35.4 | Debt to equity | 0.02 |
| 52w Index | 43.9 % | Qtr Profit Var | 7,200 % | EPS | 3.97 ₹ | Industry PE | 31.6 |
📊 Chart & Trend Analysis:
JUBLPHARMA is trading above its 50 DMA (₹950) and 200 DMA (₹982), showing short-term strength. RSI at 58.1 indicates neutral-to-bullish momentum. MACD at 22.3 confirms strong bullish crossover. Bollinger Bands place price near the mid-to-upper range, with resistance around ₹1,050–₹1,080.
📈 Momentum Signals:
- Short-term momentum is positive, but volume (64K) is far below weekly average (2.43L), showing weak participation.
- Support zone: ₹960 – ₹980.
- Resistance zone: ₹1,050 – ₹1,080.
- Break above ₹1,080 could trigger rally toward ₹1,120+, while failure to hold ₹960 may lead to consolidation.
🔎 Trend Status:
Currently trending upward with bullish undertones, but low volume raises caution.
---
Positive
✔ Price trading above both DMA levels.
✔ PAT recovery (₹6.6 Cr → ₹65.7 Cr) shows strong turnaround.
✔ Domestic institutional inflows (+0.40%).
✔ Debt-to-equity ratio at 0.02 indicates very low leverage.
✔ 52-week performance (+43.9%) reflects strong momentum.
Limitation
⚠ Extremely high P/E ratio (502) vs industry PE (31.6).
⚠ Weak ROE (1.35%) and ROCE (1.80%).
⚠ EPS at ₹3.97 reflects poor profitability.
⚠ PEG ratio (-35.4) suggests poor valuation relative to growth.
⚠ Volume participation remains weak compared to average.
Company Negative News
📉 Decline in foreign institutional holdings (-0.06%).
📉 Weak profitability metrics despite PAT recovery.
📉 Valuation concerns due to extreme multiples.
Company Positive News
📢 Strong quarterly PAT turnaround (+7,200%).
📢 Domestic institutional inflows (+0.40%).
📢 Technical breakout above DMA levels confirms bullish bias.
Industry
🌐 Industry PE at 31.6 vs JUBLPHARMA’s 502 — extreme premium valuation.
🌐 Pharma sector supported by demand for generics and specialty drugs but facing margin pressures.
Conclusion
JUBLPHARMA is trending upward with strong technical signals from DMA, RSI, and MACD. Entry near ₹960–₹980 offers favorable risk-reward, with exit targets around ₹1,050–₹1,080. Fundamentals remain weak with low ROE/ROCE and poor EPS, so traders should exercise caution and adopt strict stop-loss discipline despite short-term bullish momentum.
Would you like me to extend this into a swing trade outlook with medium-term layered targets, or refine it into an intraday momentum strategy for tighter entry/exit levels?